Safety and efficacy of tofacitinib up to 48 months in patients with active psoriatic arthritis: final analysis of the OPAL Balance long-term extension study
Peter Nash, Laura C. Coates, Dona Fleishaker, Alan Kivitz, Philip J. Mease, Dafna D. Gladman, Oliver FitzGerald, Cunshan Wang, Joseph Wu, Ming‐Ann Hsu, Sujatha Menon, Lara Fallon, Keith S. Kanik
Topics & Concepts
TofacitinibMedicinePsoriatic arthritisTolerabilityAdverse effectPlaceboJanus kinase inhibitorInternal medicineMethotrexatePsoriasisIncidence (geometry)ArthritisSurgeryRheumatoid arthritisDermatologyOpticsPathologyPhysicsAlternative medicineSpondyloarthritis Studies and TreatmentsRheumatoid Arthritis Research and TherapiesPsoriasis: Treatment and Pathogenesis